MedVector Information

MedVector is transforming how pharmaceutical companies access patients for clinical trials. For years, the industry has invested heavily in technologies designed to find patients directly. Yet enrollment challenges remain. The problem isn't a lack of recruitment tools—it's that we ask patients to join OUR path rather than meeting them on theirs. The patient journey doesn't start with a clinical trial. It starts with a diagnosis, uncertainty, and a search for answers alongside a trusted healthcare provider—often years before research enters the picture. If we meet patients on their path, we'll discover that path is filled with others facing the same condition, connected through providers they already know and trust. "Provider-Driven Enrollment" is the future of clinical research, but getting there requires more than technology. It requires deliberate transformation to overcome the industry's adoption curve. Today, much of clinical research operates in a state of "Permission to Fail"—where innovation is acceptable only when it can be isolated, minimized, or easily reversed. The challenge isn't capability; it's adoption. The first step is giving study teams "Permission to Succeed," where leadership must commit resources and apply downward pressure and accountability to facilitate change. There are several soft on-ramps where sponsors, CROs, and study teams gain confidence that new approaches can be implemented on a comfortable and controlled trajectory without increasing operational risk. The final stage is "Provider-Driven Enrollment"—a model where healthcare providers, health systems, national pharmacies, diagnostic laboratories, and payers become active and aligned enrollment channels. At this stage, research becomes part of the patient journey rather than a detour from it, creating a future where studies fill themselves. Yeah, we do that...